Open AccessPREDNISOLONE ENCAPSULATED SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES FOR TARGET DRUG DELIVERY – DESIGN AND QUANTIFICATION
Author(s) -
Subashini Rajaram,
Senthil Rajan Dharmalingam,
Santhose Rani A,
R Sapthasri,
D Varsha,
Vinodhini
Publication year - 2019
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2019.v12i11.35439
Subject(s) - prednisolone , zeta potential , drug , inflammatory bowel disease , drug delivery , budesonide , chemistry , pharmacology , iron oxide nanoparticles , coprecipitation , nanoparticle , materials science , nanotechnology , medicine , gastroenterology , corticosteroid , organic chemistry , disease
Objective: The present study aimed to develop a novel type of superparamagnetic iron oxide nanoparticles (SPIONs) to deliver prednisolone at colon as a target site for the treatment of inflammatory bowel disease (IBD) such as ulcerative colitis and Crohn’s disease which may further progress to cancer.
Methods: SPIONs were synthesized using a coprecipitation method. Further, it was encapsulated with prednisolone-polyethylene glycol by double emulsion method (W1/O/W2). The prepared formulations were characterized for its physicochemical characterization such as scanning electron microscopy, X-ray diffraction, particle size and zeta potential, encapsulation efficiency, and in vitro drug release.
Results: The results reveal that the physicochemical property of the formulations complies with the standard values and in vitro release of prednisolone in the first 18 h, attains 57 and 58% and it reaches 71 and 75% at 24 h, and this is statistically significant (p˂0.0177). This release result implies that the drug release from the formulations is controllable and sustains manner.
Conclusion: Our findings could be a promising approach for the delivery of prednisolone with enhanced half-life for the treatment of IBD through colon targeting.